PMID- 1637683
OWN - NLM
STAT- MEDLINE
DCOM- 19920902
LR  - 20190515
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 66
IP  - 1
DP  - 1992 Jul
TI  - Relationship of myc protein expression to the phenotype and to the growth 
      potential of HOC-7 ovarian cancer cells.
PG  - 93-8
AB  - In this investigation we demonstrate expression of myc oncoproteins in HOC-7 
      ovarian adenocarcinoma cells. The cells were exposed to differentiation inducing 
      agents such as dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), retinoic 
      acid (RA) and transforming growth factor-beta 1 (TGF-beta 1). Myc protein 
      expression in treated cells was then compared with that in control cultures and 
      in monoclonal HOC-7 sublines, which are characterised by distinct phenotypes. 
      Cells exposed to DMSO and DMF became markedly enlarged and flattened and 
      developed cytoplasmic extensions. They looked similar to a subline, which 
      revealed a less malignant and more differentiated cell phenotype. All four 
      inducers prolonged the cell doubling time and reduced the saturation density to 
      levels, normally found in the more differentiated subline. Furthermore, all 
      inducers except RA elevated extracellular fibronectin, which is characteristic 
      for less malignant epithelial cell phenotypes. All four agents inhibited myc 
      oncoprotein expression reversibly (1% DMSO greater than 0.5% DMF greater than 10 
      microM RA greater than 10 ng ml-1 TGF-beta 1) and in time-dependent manner. 
      Down-regulation of myc protein expression is, therefore, closely related to 
      inducer-dependent growth reduction of HOC-7 cells and to the development of a 
      less malignant cell phenotype.
FAU - Somay, C
AU  - Somay C
AD  - Department of Internal Medicine I, University of Vienna, Austria.
FAU - Grunt, T W
AU  - Grunt TW
FAU - Mannhalter, C
AU  - Mannhalter C
FAU - Dittrich, C
AU  - Dittrich C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Actins)
RN  - 0 (Fibronectins)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (Transforming Growth Factor beta)
RN  - 5688UTC01R (Tretinoin)
RN  - 8696NH0Y2X (Dimethylformamide)
RN  - YOW8V9698H (Dimethyl Sulfoxide)
SB  - IM
GS  - myc
MH  - Actins/genetics
MH  - Adenocarcinoma
MH  - Blotting, Western
MH  - Cell Differentiation/drug effects
MH  - *Cell Division
MH  - Cell Line
MH  - Dimethyl Sulfoxide/pharmacology
MH  - Dimethylformamide/pharmacology
MH  - Female
MH  - Fibronectins/analysis
MH  - Fluorescent Antibody Technique
MH  - *Genes, myc/drug effects
MH  - Humans
MH  - Ovarian Neoplasms
MH  - Phenotype
MH  - Proto-Oncogene Proteins c-myc/*analysis/genetics
MH  - Transforming Growth Factor beta/pharmacology
MH  - Tretinoin/pharmacology
PMC - PMC1977897
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
AID - 10.1038/bjc.1992.223 [doi]
PST - ppublish
SO  - Br J Cancer. 1992 Jul;66(1):93-8. doi: 10.1038/bjc.1992.223.